Cataract surgery alone should be performed first in low ECD eyes

Article

Eyes with low endothelial cell density (ECD) experienced comparable corneal endothelial damage to that of healthy eyes post-cataract surgery, indicating that only cataract surgery should be considered as the initial treatment.

A study featured in the Journal of Cataract and Refractive Surgery found that eyes with low endothelial cell density (ECD) experienced comparable corneal endothelial damage to that of healthy eyes post-cataract surgery, indicating that only cataract surgery should be considered as the initial treatment.

Dr Ken Hayashi et al., Hayashi Eye Hospital, Fukuoka, Japan, conducted a case control study on 100 eyes undergoing cataract surgery. Fifty eyes were placed into a low-density group and the remaining 50 comprised of the control group. Of the eyes in the low-density group, 39 had non-progressive endothelial pathology and 11 had Fuchs dystrophy.

Cataract surgery was performed on both groups and the ECD and central corneal thickness (CCT) were measured preoperatively and 1 and 3 months postoperatively. The increase in CCT and the percentage of cell loss were compared.

Overall, the mean ECD was significantly lower and CCT was higher in the low-density group compared to the control group. There was no significant difference in cell loss percentage was reported between the groups at 1 or 3 months postoperatively.

Based on the results the study advises that cataract surgery should be performed first without corneal transplantation.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.